Hims vs Ro for Weight Loss: Which is Better in 2026?

Hims and Ro are two of the most-searched GLP-1 telehealth providers, and for good reason: both are large, well-funded platforms with national reach and polished apps. As of May 2026, their brand-name catalogs have largely converged — both stock Wegovy (pill and pen), Zepbound, and the FDA-approved oral GLP-1 Foundayo. The differences sit elsewhere: Hims runs an official Novo Nordisk partnership and a low-friction self-pay app, while Ro adds active insurance coordination and an educational curriculum. The bottom line: if you have insurance you want to use, Ro is the stronger pick. If you're paying out of pocket, both are competitive — pick on app experience, support depth, and total ongoing cost. Here's the full breakdown.

Quick comparison

	Hims	Ro
Price (as of May 2026)	Wegovy pill from $149/mo, Foundayo from $149/mo, Zepbound from $299/mo + $149/mo membership	First-month medication from $149; ongoing $199–$449/mo + $149/mo membership ($74/mo annual)
Medication options	Wegovy (pill + pen), Foundayo, Zepbound (vial + KwikPen), Ozempic (off-label)	Wegovy (pill + pen), Zepbound KwikPen, Foundayo, compounded semaglutide (select states)
Insurance support	No prior auth assistance	Yes: active insurance coordination included
Support level	Async messaging with care team	Educational weight-loss curriculum + care messaging
Availability	All 50 states	All 50 states
Best for	Out-of-pocket patients wanting a polished brand-name self-pay app	Insured patients seeking brand-name coverage help, or patients who want annual prepay savings

Hims for weight loss

Hims entered the GLP-1 space through a partnership with Novo Nordisk, the manufacturer of Wegovy and Ozempic. That relationship gives Hims direct access to brand-name semaglutide products. As of May 2026, the Hims catalog has expanded well beyond Wegovy: Wegovy pill ($149/mo medication), Wegovy pen ($199/mo), Foundayo ($149/mo starter, escalating by dose), Zepbound (vial or KwikPen, $299/mo starter), and Ozempic ($199/mo, off-label).

Hims discontinued oral compounded semaglutide in Q1 2026 following FDA and Novo Nordisk legal pressure. The platform is now focused on FDA-approved brand-name options. All plans require a separate $149/month Hims Weight Loss Membership ($39 first month) on top of medication cost.

Hims discontinued compounded semaglutide as a primary offering after the FDA declared the semaglutide shortage resolved in early 2025 (FDA drug shortages). The platform is now focused on FDA-approved options, which represents a meaningful shift in its position.

The support model is app-based and asynchronous. You can message your care team, but there are no scheduled coaching calls or behavioral curriculum. For patients who want to handle their own routine and just need a prescription and medication, that's fine. For patients who want more structure, Hims may feel light.

One genuine advantage: Hims is available in all 50 states, and the app is well-reviewed for usability.

Hims is best for: Patients paying out of pocket who want brand-name Wegovy and prefer a low-friction app experience.

Ro for weight loss

Ro's program is built around one specific problem: getting insurance to pay for brand-name GLP-1 medications. Prior authorization for Wegovy or Zepbound is notoriously difficult. Insurers frequently deny on the first submission, and the appeals process requires clinical documentation that most patients don't know how to assemble. Ro includes insurance coordination as part of its program, meaning their care team actively helps with prior auth submissions and appeals.

Ro's brand-name catalog is comparable to Hims as of May 2026: Wegovy (pill or pen), Zepbound KwikPen, and Foundayo (orforglipron). Ro continues to offer compounded semaglutide in select states as a fallback option, though it is no longer listed on the public pricing page and surfaces only at intake based on state availability and clinical eligibility. Compounded semaglutide is not FDA-approved as a finished product.

Ro uses an introductory pricing model that's worth reading carefully (per Ro website, May 2026). First month medication: Wegovy pill $149, Wegovy pen $199, Foundayo $149, Zepbound KwikPen $299. Ongoing rates are higher and dose-dependent: Wegovy pill $199–$299/month, Wegovy pen $199–$399/month, Foundayo $199–$299/month, Zepbound KwikPen $399–$449/month. Membership runs $149/month month-to-month or $74/month on the annual plan; annual prepay also saves $50/month on Wegovy pill and $150/month on Wegovy pen. The total monthly cost depends on dose, commitment, and whether insurance covers the medication. A successful prior auth could bring your medication cost to a copay of $25–$50/month on some plans.

Ro also includes an educational weight-loss curriculum alongside the medical program. It's not intensive coaching, but it's more structured than what Hims offers.

Ro is best for: Patients with employer insurance or marketplace plans who want real help getting brand-name coverage approved. Also a good fit if you want tirzepatide (Zepbound) options.

Where they differ most

Insurance handling is the clearest dividing line. Hims does not help with prior authorization. Their model assumes you're paying out of pocket. Ro's entire value proposition for insured patients is the prior auth coordination. That's what justifies their higher membership price. If you have insurance, this difference matters more than any other factor.

Pricing structure differs. Hims uses flat self-pay pricing — the $149/mo Wegovy pill or $149/mo Foundayo starter rate doesn't escalate from month to month. Ro publishes "first month" intro rates that step up to ongoing dose-dependent pricing on month two ($50–$200/mo higher). For patients budgeting long-term, Hims's pricing is easier to model.

Medication sourcing philosophy is similar but not identical. Both went heavily into FDA-approved brand-name options after the shortage resolution. Hims pulled back entirely from compounded offerings. Ro still carries compounded semaglutide in select states as an intake-only fallback, though it's no longer listed on the public pricing page. For patients who need a cash-pay compounded option, neither platform is the cheapest path — see Henry Meds or TrimRx for that.

The catalogs are now closely matched. Both Hims and Ro stock Wegovy (pill + pen), Foundayo, and Zepbound. Hims additionally lists Ozempic for off-label use; Ro additionally has the compounded sema fallback. The historical "Ro has Zepbound, Hims doesn't" gap closed in early 2026.

Support depth is similar, but Ro has a slight edge. Neither platform offers a full behavioral coaching program. That's what Found or Noom Med are designed for. But Ro's educational curriculum is more structured than Hims's async messaging model, which is closer to a simple prescription service.

The verdict

If you have insurance: Go with Ro. The prior authorization support is the feature that could save you hundreds of dollars per month. Even if your first submission is denied, Ro's team can help you appeal, something Hims simply doesn't offer. Ro's $149/month membership is separate from medication cost, so your total depends on medication type — but a successful prior auth could bring your medication cost down dramatically.

If you're paying out of pocket and want brand-name semaglutide: Hims is competitive on flat self-pay pricing. The Wegovy pill program runs $298/month total ($149 medication + $149 membership) consistently month over month. The Wegovy pen is $348/month. Ro's Wegovy pill starts at the same first-month total but escalates by $50–$150/month on ongoing refills — so for long-term self-pay, Hims is easier to budget. The lack of coaching at Hims won't matter to patients who just want a prescription and medication delivered reliably.

If you want Foundayo (FDA-approved oral GLP-1): Both stock it. Hims and Ro both list Foundayo at $149 first-month medication. Hims holds the $149 rate going forward at the starter dose; Ro escalates to $199–$299 ongoing depending on dose.

If you're paying out of pocket and open to compounded options: Neither Hims nor Ro is the best fit. Henry Meds starts at $179/month all-inclusive for compounded semaglutide, and TrimRx offers compounded semaglutide from $199/month all-inclusive. Both skip the separate membership fee structure. Compounded semaglutide contains the same active ingredient as brand-name versions but is not FDA-approved as a finished product.

If you're still unsure which program fits your situation, the quiz below takes about 90 seconds and factors in your insurance status, budget, and medication preferences.

Before choosing any GLP-1 program, consult your healthcare provider to confirm you're an appropriate candidate for semaglutide or tirzepatide treatment.